Open AccessModification of the existing maximum residue levels for mandestrobin in apricots, cherries, peaches/nectarines and plums
Author(s) -
Brancato Alba,
Brocca Daniela,
De Lentdecker Chloe,
Erdos Zoltan,
Ferreira Lucien,
Greco Luna,
Jarrah Samira,
Kardassi Dimitra,
Leuschner Renata,
Lythgo Christopher,
Medina Paula,
Miron Ileana,
Molnar Tunde,
Nougadere Alexandre,
Pedersen Ragnor,
Reich Hermine,
Sacchi Angela,
Santos Miguel,
Stanek Alois,
Sturma Juergen,
Tarazona Jose,
Theobald Anne,
Vagenende Benedicte,
Verani Alessia,
VillamarBouza Laura
Publication year - 2018
Publication title -
efsa journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.076
H-Index - 97
ISSN - 1831-4732
DOI - 10.2903/j.efsa.2018.5148
Subject(s) - residue (chemistry) , horticulture , risk assessment , agriculture , chemistry , food science , good agricultural practice , toxicology , biology , food security , food systems , computer science , ecology , biochemistry , computer security
In accordance with Article 6 of Regulation ( EC ) No 396/2005, the applicant Sumitomo Chemical Agro Europe S.A.S. submitted a request to the competent national authority in France, to modify the existing maximum residue levels ( MRL ) for the active substance mandestrobin in apricots, cherries, peaches/nectarines and plums. The data submitted in support of the request were found to be sufficient to derive MRL proposals for apricots, cherries, peaches/nectarines and plums. Adequate analytical methods for enforcement are available to control the residues of mandestrobin in the commodities under consideration at the validated limit of quantification ( LOQ ) of 0.01 mg/kg. A short‐term dietary risk assessment was not required. Based on the long‐term risk assessment results, EFSA concluded that the long‐term intake of residues resulting from the use of mandestrobin according to the agricultural practices reported in the good agricultural practice ( GAP ) for applications at growth stages BBCH 77–87 is unlikely to present a risk to consumer health. The GAP for applications at growth stages BBCH 57–69 is not adequately supported by residue trials data. The reliable end points appropriate for use in regulatory risk assessment are presented.